A research team at the Germany-based Technical University of Munich (TUM) has, for the first time, produced dark-field x-ray images of patients infected with COVID-19. In contrast to conventional x-ray images, dark-field images visualize the microstructure of the lung tissue, thereby providing additional information. This approach has the potential to provide an alternative to CT, which requires a significantly higher radiation dose.
The lungs of COVID-19 patients are normally visualized using CT, which provides more accurate results than 2D imaging using conventional x-ray technology. The downside, however, is a higher radiation dose due to the large number of x-ray images required.
Dark-field chest x-ray is a new x-ray technology developed by the famed Franz Pfeiffer, a professor of biomedical physics and director of the Munich Institute of Biomedical Engineering at TUM. Researchers say it’s paving the road for new possibilities in radiological diagnostics.
“During our x-ray examination, we take conventional x-ray images and dark-field images simultaneously. This gives us additional information about the affected lung tissue quickly and easily,” says Pfeiffer. “The resulting radiation dose is 50 times smaller compared to CT machines.”
“Consequently, this method is promising for application scenarios that require repeated examinations over extended periods of time—for example, when investigating the progression of long COVID,” he adds. “This approach might serve as an alternative to CT for imaging lung tissue over prolonged observation periods.”
Additional Information on Lung Tissue Microstructure
In a new study, radiologists compared the images of patients with COVID-19 lung disease to those of healthy individuals. They found that distinguishing between sick and healthy individuals was easier using dark-field images than conventional x-ray images. The radiologists were able to differentiate between diseased and healthy lung tissue most readily when both kinds of images—conventional and darkfield—were available.
While conventional x-ray technology relies on the attenuation of x-rays, dark-field x-ray technology utilizes so-called small-angle x-ray scattering. This opens the door to garner additional information on the nature of lung tissue microstructure. Dark-field images can thus provide added value when investigating a variety of lung diseases.
Quantitative Evaluation
The research team optimized the x-ray machine prototype to allow them to evaluate the images quantitatively. A healthy lung with many intact alveoli produces a strong dark-field signal and appears bright in the image. In contrast, inflamed lung tissue, with embedded fluid, produces a weaker signal and appears darker in the image.
“We normalize the dark-field signal with regard to lung volume to account for lung volume variations between individuals,” explains Manuela Frank, a lead author of the paper.
“Next, we hope to examine further patients. Once we have sufficient dark field x-ray data available, we intend to use artificial intelligence to support the evaluation process. For conventional images, we have already carried out a pilot project for AI evaluation of our x-ray images,” adds Daniela Pfeiffer, MHBA, professor of radiology and medical director of the study at the TUM University hospital Klinikum rechts der Isar.
More Information on the New Dark-Field X-ray Technology
Dark field x-ray is a novel medical examination method. Pfeiffer and his team developed the method from the ground up and have been advancing it continuously for more than 10 years, making it available for the world-wide first use in patients.
In close cooperation with radiologists at the TUM University hospital Klinikum rechts der Isar, the researchers developed the dark field x-ray prototype which has been approved for initial clinical studies. The prototype is currently being used in several studies with patients suffering from various lung diseases. Following an initial study on chronic obstructive pulmonary disease, or COPD, and COVID-19, the technology might also be deployed in the future for other lung pathologies such as lung cancer, fibrosis, or pneumothorax.
